Patents by Inventor Sung-Sau So

Sung-Sau So has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIVIRAL COMPOUNDS
    Publication number: 20120328565
    Abstract: The present invention discloses compounds of Formula I wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the treatment of HCV infection.
    Type: Application
    Filed: June 21, 2012
    Publication date: December 27, 2012
    Inventors: John A. Brinkman, Andrew F. Donnell, Robert Francis Kester, Yimin Qian, Ramakanth Sarabu, Sung-Sau So
  • BENZOCYCLOHEPTENE ACETIC ACIDS
    Publication number: 20120309796
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, asthma and COPD.
    Type: Application
    Filed: May 11, 2012
    Publication date: December 6, 2012
    Inventors: Fariborz Firooznia, Paul Gillespie, Tai-An Lin, Sung-Sau So
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20120295885
    Abstract: This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.
    Type: Application
    Filed: May 16, 2012
    Publication date: November 22, 2012
    Inventors: Roland Joseph Billedeau, Rama K. Kondru, Francisco Javier Lopez-Tapia, Yan Lou, Timothy D. Owens, Yimin Qian, Sung-Sau So, Kshitij C. Thakkar, Jutta Wanner
  • Sultam derivatives
    Patent number: 8314250
    Abstract: The present invention relates to compounds according to formula 1, which exhibit cytotoxic activity. The compounds may be used in the treatment of cancer.
    Type: Grant
    Filed: October 15, 2010
    Date of Patent: November 20, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Kevin W. Anderson, Paul Gillespie, Nicholas J. S. Huby, Norman Kong, John L. Roberts, Pamela L. Rossman, Sung-Sau So
  • Aminotetrahydroindazoloacetic acids
    Patent number: 8268870
    Abstract: The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Q, R1-R3 and n are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: September 18, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Li Chen, Fariborz Firooznia, Paul Gillespie, Yun He, Tai-An Lin, Sung-Sau So, HongYing Yun
  • ANTIVIRAL COMPOUNDS
    Publication number: 20120230951
    Abstract: The present invention provides compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Application
    Filed: March 8, 2012
    Publication date: September 13, 2012
    Inventors: Muzaffar Alam, Steven Joseph Berthel, John A. Brinkman, Ronald Charles Hawley, Hongju Li, Wylie Solang Palmer, Sherrie Pietranico-Cole, Ramakanth Sarabu, Mark Smith, Sung-Sau So, Lin Yi, Yansheng Zhai, Qiang Zhang, Shu-Hai Zhao
  • Substituted aminotetralines
    Patent number: 8263656
    Abstract: The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein R1-R4 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.
    Type: Grant
    Filed: August 13, 2009
    Date of Patent: September 11, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Fariborz Firooznia, Paul Gillespie, Robert Alan Goodnow, Jr., Tai-An Lin, Achyutharao Sidduri, Sung-Sau So, Jenny Tan
  • Azaindole glucokinase activators
    Patent number: 8222416
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: July 17, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Steven Joseph Berthel, Li Chen, Wendy Lea Corbett, Lichun Feng, Nancy-Ellen Haynes, Robert Francis Kester, Sung-Sau So, Jefferson Wright Tilley
  • Naphthylacetic acids
    Patent number: 8188090
    Abstract: The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein X, Q and R1-R3 are defined in the detailed description and claims. The invention is also concerned with the compounds of formula Z: and pharmaceutically acceptable salts and esters thereof, wherein R1-R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I and Z as well as pharmaceutical compositions containing such compounds. The compounds of formula I and Z are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: May 29, 2012
    Assignee: Hoffman-La Roche Inc.
    Inventors: Fariborz Firooznia, Tai-An Lin, Sung-Sau So, Baoxia Wang, HongYing Yun
  • Aminotetrahydroindazoloacetic Acids
    Publication number: 20120101131
    Abstract: The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Q, W, X, R1-R5 and n are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.
    Type: Application
    Filed: January 2, 2012
    Publication date: April 26, 2012
    Inventors: Li Chen, Fariborz Firooznia, Paul Gillespie, Yun He, Tai-An Lin, Sung-Sau So, HongYing Yun, Zhenshan Zhang
  • Bi-aryl aminotetralines
    Patent number: 8163781
    Abstract: The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein R1-R5, A, B, Q, W, and X are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.
    Type: Grant
    Filed: August 13, 2009
    Date of Patent: April 24, 2012
    Assignee: Hoffman-La Roche Inc.
    Inventors: Jean-Baptiste Blanc, Li Chen, Fariborz Firooznia, Paul Gillespie, Robert Alan Goodnow, Jr., Yun He, Tai-An Lin, Sung-Sau So, HongYing Yun, Zhenshan Zhang
  • AMINOTETRAHYDROINDAZOLOACETIC ACIDS
    Publication number: 20120095053
    Abstract: The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Q, R1-R3 and n are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.
    Type: Application
    Filed: December 13, 2011
    Publication date: April 19, 2012
    Inventors: Li Chen, Fariborz Firooznia, Paul Gillespie, Yun He, Tai-An Lin, Sung-Sau So, HongYing Yun
  • Aminotetrahydroindazoloacetic acids
    Patent number: 8138208
    Abstract: The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Q, W, X, R1-R5 and n are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.
    Type: Grant
    Filed: July 6, 2009
    Date of Patent: March 20, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Li Chen, Fariborz Firooznia, Paul Gillespie, Yun He, Tai-An Lin, Sung-Sau So, HongYing Yun, Zhenshan Zhang
  • Aminotetrahydroindazoloacetic acids
    Patent number: 8124641
    Abstract: The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Q, R1-R3 and n are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.
    Type: Grant
    Filed: July 6, 2009
    Date of Patent: February 28, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Li Chen, Fariborz Firooznia, Paul Gillespie, Yun He, Tai-An Lin, Sung-Sau So, HongYing Yun
  • Naphthylacetic acids
    Patent number: 8124629
    Abstract: The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein X, Q, and R1-R6 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: February 28, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Fariborz Firooznia, Paul Gillespie, Tai-An Lin, Eric Mertz, Achyutharao Sidduri, Sung-Sau So, Jenny Tan, Kshitij Chhabilbhai Thakkar
  • Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists
    Publication number: 20120046306
    Abstract: There are provided compounds of the general formula wherein A, B, V, W, R1, R2, R3, R3, and R4, are as described herein and enantiomers and pharmaceutically acceptable salts thereof. The compounds are useful as anticancer agents.
    Type: Application
    Filed: July 12, 2011
    Publication date: February 23, 2012
    Inventors: David Joseph Bartkovitz, Xin-Jie Chu, Qingjie Ding, Prabha Saba Karnachi, Jin-Jun Liu, Sung-Sau So, Jing Zhang, Zhuming Zhang
  • AZAINDOLE GLUCOKINASE ACTIVATORS
    Publication number: 20110144105
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.
    Type: Application
    Filed: November 10, 2010
    Publication date: June 16, 2011
    Inventors: Steven Joseph Berthel, Li Chen, Wendy Lea Corbett, LiChun Feng, Nancy-Ellen Haynes, Robert Francis Kester, Sung-Sau So, Jefferson Wright Tilley
  • SULTAM DERIVATIVES
    Publication number: 20110124686
    Abstract: The present invention relates to compounds according to formula 1, which exhibit cytotoxic activity. The compounds may be used in the treatment of cancer.
    Type: Application
    Filed: October 15, 2010
    Publication date: May 26, 2011
    Inventors: Kevin W. Anderson, Paul Gillespie, Nicholas J. S. Huby, Norman Kong, John L. Roberts, Pamela L. Rossman, Sung-Sau So
  • Substituted thieno[3,2-C]pyridine carboxylic acid derivatives
    Patent number: 7932390
    Abstract: There are provided compounds of the formula wherein R1, R2, R3, X, ring A and ring B are as described. The compounds exhibit anticancer properties.
    Type: Grant
    Filed: June 18, 2007
    Date of Patent: April 26, 2011
    Assignee: Hoffman-La Roche Inc.
    Inventors: Yi Chen, Kin-Chun Luk, Pamela Loreen Rossman, Sung-Sau So
  • 4,4,5,5, tetrasubstituted imidazolines
    Patent number: 7851626
    Abstract: There is provided a compound of formula I and the pharmaceutically acceptable salts and esters thereof wherein X1, X2, R1, R2, R3, R4, R5 and R6 are herein described. The compounds exhibit activity as anticancer agents.
    Type: Grant
    Filed: November 27, 2006
    Date of Patent: December 14, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Qingjie Ding, Bradford James Graves, Norman Kong, Jin-Jun Liu, Allen John Lovey, Giacomo Pizzolato, John Lawson Roberts, Sung-Sau So, Binh Thanh Vu, Peter Michael Wovkulich